Literature DB >> 3323165

Roxithromycin in the therapy of Streptococcus pyogenes throat infections.

J M Herron1.   

Abstract

Roxithromycin in two dosage regimens was compared with erythromycin in the therapy of 227 patients with throat infectious due to Streptococcus pyogenes. All three groups had the same clinical efficacy but roxithromycin 300 mg daily was less effective than erythromycin 500 mg qds in eradicating S. pyogenes while there were less antibiotic-related side effects with roxithromycin 150 mg bd than with erythromycin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323165     DOI: 10.1093/jac/20.suppl_b.139

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

2.  Roxithromycin versus cefaclor in lower respiratory tract infection: a general practice pharmacoeconomic study.

Authors:  W G Scott; M W Tilyard; S M Dovey; B Cooper; H M Scott
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

3.  The use of macrolides in respiratory tract infections.

Authors:  J C Pechère
Journal:  Int J Antimicrob Agents       Date:  1993-11       Impact factor: 5.283

Review 4.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

5.  The Place of Macrolides in the Treatment of Upper Respiratory Tract Infections.

Authors:  D Gómez-Barreto
Journal:  Drug Investig       Date:  2012-10-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.